Cantargia AB
STO:CANTA
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.889
5
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CANTA stock under the Base Case scenario is 0.877 SEK. Compared to the current market price of 1.916 SEK, Cantargia AB is Overvalued by 54%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Cantargia AB
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CANTA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Cantargia AB
Balance Sheet Decomposition
Cantargia AB
Current Assets | 114.2m |
Cash & Short-Term Investments | 104.7m |
Receivables | 1.2m |
Other Current Assets | 8.3m |
Non-Current Assets | 7.8m |
PP&E | 3.6m |
Intangibles | 4.2m |
Current Liabilities | 31.1m |
Accounts Payable | 11.5m |
Accrued Liabilities | 17.6m |
Other Current Liabilities | 2m |
Non-Current Liabilities | 278k |
Other Non-Current Liabilities | 278k |
Earnings Waterfall
Cantargia AB
Revenue
|
0
SEK
|
Operating Expenses
|
-235.3m
SEK
|
Operating Income
|
-235.3m
SEK
|
Other Expenses
|
7.4m
SEK
|
Net Income
|
-228m
SEK
|
Free Cash Flow Analysis
Cantargia AB
SEK | |
Free Cash Flow | SEK |
Cantargia reported exciting advancements in its CAN10 and nadunolimab (CAN04) clinical programs. The CAN10 program showed promising safety data and biomarker results in the Phase I trial, with plans to enter Phase II next year. Nadunolimab exhibited beneficial effects in pancreatic and triple-negative breast cancer trials, with a Phase IIb pancreatic cancer trial planned. Operational expenses decreased by 39% to SEK 85 million in the first half of the year, owing to reduced R&D costs. The company’s financial runway, with SEK 105 million in available funds, is expected to last until early next year.
What is Earnings Call?
CANTA Profitability Score
Profitability Due Diligence
Cantargia AB's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Cantargia AB's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
CANTA Solvency Score
Solvency Due Diligence
Cantargia AB's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
Cantargia AB's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CANTA Price Targets Summary
Cantargia AB
According to Wall Street analysts, the average 1-year price target for CANTA is 9.894 SEK with a low forecast of 5.05 SEK and a high forecast of 14.7 SEK.
Dividends
Current shareholder yield for CANTA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cantargia AB is a holding company, which engages in the development of antibody-based cancer treatment. The company is headquartered in Lund, Skane. The company went IPO on 2015-03-17. The firm is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
Officers
The intrinsic value of one CANTA stock under the Base Case scenario is 0.877 SEK.
Compared to the current market price of 1.916 SEK, Cantargia AB is Overvalued by 54%.